Literature DB >> 32807060

Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials.

Godela M Brosnahan1, Zhiying You1, Wei Wang1, Berenice Y Gitomer1, Michel Chonchol1.   

Abstract

BACKGROUND: Epidemiological studies have suggested that elevated serum uric acid may contribute to the progression of chronic kidney disease. However, no large prospective study has examined whether hyperuricemia is an independent risk factor for the progression of autosomal dominant polycystic kidney disease (ADPKD).
METHODS: We measured uric acid in stored serum samples from the 2-year study visit of 671 participants from the HALT PKD multicenter trials. Participants were categorized according to uric acid tertiles. For Study A (participants aged 15-49 years with preserved kidney function, n=350), we used linear mixed effects models to examine the association between uric acid and repeated measures of height-adjusted total kidney volume (htTKV), the primary outcome for Study A. For Study B (participants aged 18-64 with decreased kidney function, n=321), we used Cox proportional hazards models to assess the hazard for the combined endpoint of 50% loss in estimated glomerular filtration rate (eGFR), end-stage kidney disease (ESKD), or death, the primary outcome for Study B. To assess the association of uric acid with the slope of eGFR decline (secondary outcome of HALT A and B), we used linear mixed effects models for the combined population of Study A and B.
RESULTS: In the unadjusted model, the annual change in htTKV was 2.7% higher in the highest uric acid tertile compared to the lowest (p<0.001), but this difference became insignificant after adjustment for gender. Men had faster TKV growth than women (p<0.001). There was no difference in eGFR decline between the 3 uric acid tertiles. Hazard ratios for the clinical endpoint were 2.9 (95% confidence interval, 1.9-4.4) and 1.8 (1.1-2.8) respectively in the high and medium uric acid groups in unadjusted and partially adjusted models (p<0.001), but the significance was lost after adjustment for baseline eGFR. Results were similar when uric acid was examined as a continuous variable.
CONCLUSION: Elevated serum uric acid is not an independent risk factor for disease progression in ADPKD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Autosomal dominant polycystic kidney disease; HALT PKD trials; chronic kidney disease.; estimated glomerular filtrationzzm321990rate; serum uric acid; total kidney volume

Mesh:

Substances:

Year:  2021        PMID: 32807060      PMCID: PMC7887140          DOI: 10.2174/1573402116666200817113125

Source DB:  PubMed          Journal:  Curr Hypertens Rev        ISSN: 1573-4021


  47 in total

1.  Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction.

Authors:  Min-A Yu; Laura G Sánchez-Lozada; Richard J Johnson; Duk-Hee Kang
Journal:  J Hypertens       Date:  2010-06       Impact factor: 4.844

Review 2.  Why kidneys fail in autosomal dominant polycystic kidney disease.

Authors:  Jared J Grantham; Sumanth Mulamalla; Katherine I Swenson-Fields
Journal:  Nat Rev Nephrol       Date:  2011-08-23       Impact factor: 28.314

3.  Elevated Serum Uric Acid Level Predicts Rapid Decline in Kidney Function.

Authors:  Masanari Kuwabara; Petter Bjornstad; Ichiro Hisatome; Koichiro Niwa; Carlos A Roncal-Jimenez; Ana Andres-Hernando; Thomas Jensen; Tamara Milagres; Yuka Sato; Gabriela Garcia; Minoru Ohno; Miguel A Lanaspa; Richard J Johnson
Journal:  Am J Nephrol       Date:  2017-03-11       Impact factor: 3.754

4.  Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease.

Authors:  P A Gabow; A M Johnson; W D Kaehny; W J Kimberling; D C Lezotte; I T Duley; R H Jones
Journal:  Kidney Int       Date:  1992-05       Impact factor: 10.612

5.  A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.

Authors:  Mehmet Kanbay; Bulent Huddam; Alper Azak; Yalcin Solak; Gulay Kocak Kadioglu; Ismail Kirbas; Murat Duranay; Adrian Covic; Richard J Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

6.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

7.  A role for uric acid in the progression of renal disease.

Authors:  Duk-Hee Kang; Takahiko Nakagawa; Lili Feng; Susumu Watanabe; Lin Han; Marilda Mazzali; Luan Truong; Raymond Harris; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2002-12       Impact factor: 10.121

8.  Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.

Authors:  Owen M Woodward; Anna Köttgen; Josef Coresh; Eric Boerwinkle; William B Guggino; Michael Köttgen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-08       Impact factor: 11.205

9.  Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Kristen L Nowak; Wei Wang; Heather Farmer-Bailey; Berenice Gitomer; Mikaela Malaczewski; Jelena Klawitter; Anna Jovanovich; Michel Chonchol
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-18       Impact factor: 8.237

10.  Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study.

Authors:  Peter Hovind; Peter Rossing; Lise Tarnow; Richard J Johnson; Hans-Henrik Parving
Journal:  Diabetes       Date:  2009-05-01       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.